New biotechnological and nanomedicine strategies for treatment of lysosomal storage disorders

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 2, Issue 2, 2010, Pages 189-204

  Muro, Silvia ^a,b  

^a UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL THERAPY; CHEMICAL CHAPERONE; DRUG CARRIER; ENZYME REPLACEMENT THERAPY; GENETIC DISEASE; LYSOSOMAL STORAGE DISORDER; NANOMEDICINES; TREATMENT MODALITY;

GENE THERAPY; MEDICAL NANOTECHNOLOGY; STRATEGIC PLANNING;

DRUG THERAPY;

BETA GLUCURONIDASE; CEREBROSIDE SULFATASE; CYCLODEXTRIN; DEXAMETHASONE; INTERCELLULAR ADHESION MOLECULE 1; LYSOSOME ENZYME; MACROGOL; NANOCARRIER; VIRUS VECTOR;

BIOTECHNOLOGY; BONE MARROW TRANSPLANTATION; CELL THERAPY; CHIMERA; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG TARGETING; DRUG UPTAKE; ENZYME REPLACEMENT; GENE THERAPY; GENETIC DISORDER; HUMAN; LYSOSOME STORAGE DISEASE; METACHROMATIC LEUKODYSTROPHY; NANOMEDICINE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSCYTOSIS;

ANIMALS; BIOTECHNOLOGY; DRUG DELIVERY SYSTEMS; ENZYME REPLACEMENT THERAPY; GENE THERAPY; HUMANS; LYSOSOMAL STORAGE DISEASES; NANOMEDICINE;

EID: 77953679847     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.73     Document Type: Review

References (120)

1. Sabatini DD, Adesnik MB. The biogenesis of membranes and organelles. In: Scriver C, Beaudet A, Sly W, Valle D, Childs B, et al. eds. Lysosomal Disorders the Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill; 2001.
2. Scriver C, Beaudet A, Sly W, Valle D, Childs B, et al. The Metabolic andMolecular Bases of Inherited Disease. 8th edn. New York: McGraw-Hill; 2001.
3. Futerman AH, van Meer G. The cell biology of lysosomal storage disorders. Nat Rev Mol Cell Biol 2004, 5:554-565.
4. Meikle PJ,Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. J Am Med Assoc 1999, 281:249-254.
5. Schuchman EH, Desnick RJ. Niemann-Pick disease types A and B: acid sphingomyelinase deficiencies. In: Scriver C, Beaudet A, Sly W, Valle D, Childs B, et al. B, eds. Lysosomal Disorders the Metabolic and Molecular Bases of Inherited Disease. NewYork: McGraw-Hill; 2001, 3589-3610.
6. Schmitz J, Poll LW, vom Dahl S. Therapy of adult Gaucher disease. Haematologica 2007, 92:148-152.
7. Malatack JJ, Consolini DM, Bayever E. The status of hematopoietic stem cell transplantation in lysosomal storage disease. Pediatr Neurol 2003, 29:391-403.
8. Krivit W. Stem cell bone marrow transplantation in patients with metabolic storage diseases. Adv Pediatr 2002, 49:359-378.
9. Jin HK, Carter JE, Huntley GW, Schuchman EH. Intracerebral transplantation of mesenchymal stem cells into acid sphingomyelinase-deficient mice delays the onset of neurological abnormalities and extends their life span. J Clin Invest 2002, 109:1183-1191.
10. Shihabuddin LS, Numan S, Huff MR, Dodge JC, Clarke J, et al. Intracerebral transplantation of adult mouse neural progenitor cells into the Niemann-Pick-A mouse leads to a marked decrease in lysosomal storage pathology. J Neurosci 2004, 24:10642-10651.
11. Vellodi A, Young EP, Cooper A, Wraith JE, Winchester B, et al. Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British Centres. Arch Dis Child 1997, 76:92-99.
12. Ellinwood NM, Vite CH, Haskins ME. Gene therapy for lysosomal storage diseases: the lessons and promise of animal models. J Gene Med 2004, 6:481-506.
13. Eto Y, Ohashi T. Gene therapy/cell therapy for lysosomal storage disease. J Inherit Metab Dis 2000, 23:293-298.
14. Haskins M. Gene therapy for lysosomal storage diseases (LSDs) in large animal models. ILAR J 2009, 50:112-121.
15. Hodges BL, Cheng SH. Cell and gene-based therapies for the lysosomal storage diseases. Curr Gene Ther 2006, 6:227-241.
16. Ponder KP, Haskins ME. Gene therapy for mucopolysaccharidosis. Expert Opin Biol Ther 2007, 7:1333-1345.
17. Sands MS, Davidson BL. Gene therapy for lysosomal storage diseases. Mol Ther 2006, 13:839-849.
18. Karolewski BA, Wolfe JH. Genetic correction of the fetal brain increases the lifespan of mice with the severe multisystemic disease mucopolysaccharidosis type VII. Mol Ther 2006, 14:14-24.
19. Miranda SR, He X, Simonaro CM, Gatt S, Dagan A, et al. Infusion of recombinant human acid sphingomyelinase into Niemann-Pick disease mice leads to visceral, but not neurological, correction of the pathophysiology. FASEB J 2000, 14:1988-1995.
20. Ohashi T, Yokoo T, Iizuka S, Kobayashi H, Sly WS, et al. Reduction of lysosomal storage in murine mucopolysaccharidosis type VII by transplantation of normal and genetically modified macrophages. Blood 2000, 95:3631-3633.
21. Sands MS, Haskins ME. CNS-directed gene therapy for lysosomal storage diseases. Acta Paediatr Suppl 2008, 97:22-27.
22. Yang WW, Dodge JC, Passini MA, Taksir TV, Griffiths D, et al. Intraparenchymal injections of acid sphingomyelinase results in regional correction of lysosomal storage pathology in the Niemann-Pick A mouse. Exp Neurol 2007, 207:258-266.
23. Butters TD, Mellor HR, Narita K, Dwek RA, Platt FM. Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders. Philos Trans R Soc Lond B Biol Sci 2003, 358:927-945.
24. Radin NS. Treatment of Gaucher disease with an enzyme inhibitor. Glycoconj J 1996, 13:153-157.
25. Alfonso P, Pampin S, Estrada J, Rodriguez-Rey JC, Giraldo P, et al. Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations. Blood Cells Mol Dis 2005, 35:286-276.
26. Yam GH, Zuber C, Roth J. A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder. FASEB J 2005, 19:12-18.
27. Narita K, Choudhury A, Dobrenis K, Sharma DK, Holicky EL, et al. Protein transduction of Rab9 in Niemann-Pick C cells reduces cholesterol storage. FASEB J 2005, 19:1558-1560.
28. Camargo F, Erickson RP, Garver WS, Hossain GS, Carbone PN, et al. Cyclodextrins in the treatment of a mouse model of Niemann-Pick C disease. Life Sci 2001, 70:131-142.
29. Wasser CR, Ertunc M, Liu X, Kavalali ET. Cholesterol-dependent balance between evoked and spontaneous synaptic vesicle recycling. J Physiol 2007, 579:413-429.
30. Lange Y, Ye J, RigneyM, Steck TL. Dynamics of lysosomal cholesterol inNiemann-Pick type C and normal human fibroblasts. J Lipid Res 2002, 43:198-204.
31. Brady RO. Enzyme replacement therapy: Conception, chaos and culmination. Philos Trans R Soc Lond B Biol Sci 2003, 358:915-919.
32. Desnick RJ, Schuchman EH. Enzyme replacement and enhancement therapies: lessons from lysosomal disorders. Nat Rev Genet 2002, 3:954-966.
33. Schuchman EH,Muro, S. The development of enzyme replacement therapy for lysosomal diseases: Gaucher disease and beyond. In: Futerman AH, ed. Gaucher Disease: Lessons Learned About Therapy of Lysosomal Disorders. New York: CRC Press; 2006, 125-140.
34. Kornfeld S, ReitmanML, Varki A, Goldberg D, Gabel CA. Steps in the phosphorylation of the high mannose oligosaccharides of lysosomal enzymes. Ciba Found Symp 1982, 92:138-156.
35. Lee WS, Rohrer J, Kornfeld R, Kornfeld S. Multiple signals regulate trafficking of the mannose 6-phosphate-uncovering enzyme. J Biol Chem 2002, 277:3544-3551.
36. RosenfeldMG, Kreibich G, Popov D, Kato K, Sabatini DD. Biosynthesis of lysosomal hydrolases: their synthesis in bound polysomes and the role of co- and post-translational processing in determining their subcellular distribution. J Cell Biol 1982, 93:135-143.
37. Neufeld EF. The uptake of enzymes into lysosomes: an overview. Birth Defects Orig Artic Ser 1980, 16:77-84.
38. Kaplan A, Achord DT, SlyWS. Phosphohexosyl components of a lysosomal enzyme are recognized by pinocytosis receptors on human fibroblasts. Proc Natl Acad Sci USA 1977, 74:2026-2030.
39. Mistry PK, Wraight EP, Cox TM. Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher's disease. Lancet 1996, 348:1555-1559.
40. Barton RW, Neufeld EF. The Hurler corrective factor. Purification and some properties. J Biol Chem 1971, 246:7773-7779.
41. O'Brien JS, Miller AL, Loverde AW, Veath ML. Sanfilippo disease type B: enzyme replacement and metabolic correction in cultured fibroblasts. Science 1973, 181:753-755.
42. Porter MT, Fluharty AL, Kihara H. Correction of abnormal cerebroside sulfate metabolism in cultured metachromatic leukodystrophy fibroblasts. Science 1971, 172:1263-1265.
43. De Duve C. The significance of lysosomes in pathology and medicine. Proc Inst Med Chic 1966, 26:73-76.
44. Furbish FS, Steer CJ, Krett NL, Barranger JA. Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation. Biochim Biophys Acta 1981, 673:425-434.
45. Murray GJ. Lectin-specific targeting of lysosomal enzymes to reticuloendothelial cells. Methods Enzymol 1987, 149:25-42.
46. Zhu Y, Li X, Schuchman EH, Desnick RJ, Cheng SH. Dexamethasone-mediated up-regulation of the mannose receptor improves the delivery of recombinant glucocerebrosidase to Gaucher macrophages. J Pharmacol Exp Ther 2004, 308:705-711.
47. Achord DT, Brot FE, Bell CE, Sly WS. Human beta-glucuronidase: in vivo clearance and in vitro uptake by a glycoprotein recognition system on reticuloendothelial cells. Cell 1978, 15:269-278.
48. Kornfeld S. Trafficking of lysosomal enzymes. FASEB J 1987, 1:462-468.
49. Sands MS, Vogler CA, Ohlemiller KK, Roberts MS, Grubb JH, et al. Biodistribution, kinetics, and efficacy of highly phosphorylated and non-phosphorylated beta-glucuronidase in the murine model of mucopolysaccharidosis VII. J Biol Chem 2001, 276:43160-43165.
50. Morgan DO, Edman JC, Standring DN, Fried VA, SmithMC, et al. Insulin-like growth factor II receptor as a multifunctional binding protein. Nature 1987, 329:301-307.
51. LeBowitz JH, Grubb JH, Maga JA, Schmiel DH, Vogler C, et al. Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice. Proc Natl Acad Sci USA 2004, 101:3083-3088.
52. Green I, Christison R, Voyce CJ, Bundell KR, Lindsay MA. Protein transduction domains: are they delivering? Trends Pharmacol Sci 2003, 24:213-215.
53. Vaags AK, Campbell TN, Choy FY. HIV Tat variants differentially influence the production of glucocerebrosidase in sf9 cells. Genet Mol Res 2005, 4:491-495.
54. Xia H, Mao Q, Davidson BL. The HIV Tat protein transduction domain improves the biodistribution of beta-glucuronidase expressed from recombinant viral vectors. Nat Biotechnol 2001, 19:640-644.
55. Urayama A, Grubb JH, Sly WS, Banks WA. Mannose 6-phosphate receptor-mediated transport of sulfamidase across the blood-brain barrier in the newborn mouse. Mol Ther 2008, 16:1261-1266.
56. Boado RJ, Zhang Y, Xia CF,Wang Y, Pardridge WM. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human bloodbrain barrier. Biotechnol Bioeng 2008, 99:475-484.
57. Lee KO, Luu N, Kaneski CR, Schiffmann R, Brady RO, et al. Improved intracellular delivery of glucocerebrosidase mediated by the HIV-1 Tat protein transduction domain. Biochem Biophys Res Commun 2005, 337:701-707.
58. Prince WS, McCormick LM, Wendt DJ, Fitzpatrick PA, Schwartz KL, et al. Lipoprotein receptor binding, cellular uptake, and lysosomal delivery of fusions between the receptor-associated protein (RAP) and alpha-L-iduronidase or acid alpha-glucosidase. J Biol Chem 2004, 279:35037-35046.
59. Li Y, Lu W, Schwartz AL, Bu G. Receptor-associated protein facilitates proper folding and maturation of the low-density lipoprotein receptor and its class 2 mutants. Biochemistry 2002, 41:4921-4928.
60. Czekay RP, Orlando RA, Woodward L, Lundstrom M, Farquhar MG. Endocytic trafficking of megalin/rap complexes. Dissociation of the complexes in late endosomes.Mol Biol Cell 1997, 8:517-532.
61. Brooks H, Lebleu B, Vives E. Tat peptide-mediated cellular delivery: back to basics. Adv Drug Deliv Rev 2005, 57:559-577.
62. Zhang XY, Dinh A, Cronin J, Li SC, Reiser J. Cellular uptake and lysosomal delivery of galactocerebrosidase tagged with the HIV Tat protein transduction domain. J Neurochem 2008, 104:1055-1064.
63. Dejana E. Endothelial cell-cell junctions: happy together. Nat Rev Mol Cell Biol 2004, 5:261-270.
64. Mehta D, Bhattacharya J, Matthay MA, Malik AB. Integrated control of lung fluid balance. Am J Physiol Lung Cell Mol Physiol 2004, 287:L1081-L1090.
65. Minshall RD, Tiruppathi C, Vogel SM, Malik AB. Vesicle formation and trafficking in endothelial cells and regulation of endothelial barrier function. Histochem Cell Biol 2002, 117:105-112.
66. Abbott NJ, Romero IA. Transporting therapeutics across the blood-brain barrier. Mol Med Today 1996, 2:106-113.
67. Lo EH, Singhal AB, Torchilin VP, Abbott NJ. Drug delivery to damaged brain. Brain Res Brain Res Rev 2001, 38:140-148.
68. Mahoney MJ, Saltzman WM. Controlled release of proteins to tissue transplants for the treatment of neurodegenerative disorders. J Pharm Sci 1996, 85:1276-1281.
69. Thai QA, Pradilla G, Legnani FG, Kretzer RM, Hsu W, et al. Lysis of intracerebral hematoma with stereotactically implanted tissue plasminogen activator polymers in a rabbit model. J Neurosurg 2006, 105:424-429.
70. Voges J, Reszka R, Gossmann A, Dittmar C, Richter R, et al. Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol 2003, 54:479-487.
71. Feng D, Nagy JA, Dvorak HF, Dvorak AM. Ultrastructural studies define soluble macromolecular, particulate, and cellular transendothelial cell pathways in venules, lymphatic vessels, and tumor-associated microvessels in man and animals. Microsc Res Tech 2002, 57:289-326.
72. Pardridge WM. Molecular trojan horses for bloodbrain barrier drug delivery. Curr Opin Pharmacol 2006, 6:494-500.
73. Predescu D, Vogel SM, Malik AB. Functional and morphological studies of protein transcytosis in continuous endothelia. Am J Physiol Lung Cell Mol Physiol 2004, 287:L895-L901.
74. Stevens T, Garcia JG, Shasby DM, Bhattacharya J, Malik AB. Mechanisms regulating endothelial cell barrier function. Am J Physiol Lung Cell Mol Physiol 2000, 279:L419-L422.
75. Osborn MJ, McElmurry RT, Peacock B, Tolar J, Blazar BR. Targeting of the CNS in MPS-IH using a nonviral transferrin-alpha-L-iduronidase fusion gene product. Mol Ther 2008, 16:1459-1466.
76. Ohashi T, Iizuka S, Ida H, Eto Y. Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease. Mol Genet Metab 2008, 94:313-318.
77. Matzner U, Matthes F, Weigelt C, Andersson C, Eistrup C, et al. Non-inhibitory antibodies impede lysosomal storage reduction during enzyme replacement therapy of a lysosomal storage disease. J Mol Med 2008, 86:433-442.
78. Ponder KP. Immune response hinders therapy for lysosomal storage diseases. J Clin Invest 2008, 118:2686-2689.
79. Mumtaz S, Bachhawat BK. Enhanced intracellular stability and efficacy of PEG modified dextranase in the treatment of a model storage disorder. Biochim Biophys Acta 1994, 1199:175-182.
80. Ansari NH, He Q, Cook JD, Wen J, Srivastava SK. Delivery of liposome-sequestered hydrophobic proteins to lysosomes of normal and Batten disease cells. J Neurosci Res 1997, 47:341-347.
81. Steger LD, Desnick RJ. Enzyme therapy. VI: comparative in vivo fates and effects on lysosomal integrity of enzyme entrapped in negatively and positively charged liposomes. Biochim Biophys Acta 1977, 464:530-546.
82. Weissmann G, Bloomgarden D, Kaplan R, Cohen C, Hoffstein S, et al. A general method for the introduction of enzymes, by means of immunoglobulin- coated liposomes, into lysosomes of deficient cells. Proc Natl Acad Sci USA 1975, 72:88-92.
83. Muro S, Dziubla T, Qiu W, Leferovich J, Cui X, et al. Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1. J Pharmacol Exp Ther 2006, 317:1161-1169.
84. Garnacho C, Albelda SM, Muzykantov VR, Muro S. Differential intra-endothelial delivery of polymer nanocarriers targeted to distinct PECAM-1 epitopes. J Control Release 2008, 130:226-233.
85. Bloemen PG, Henricks PA, van Bloois L, van den Tweel MC, Bloem AC, et al. Adhesion molecules: A new target for immunoliposome-mediated drug delivery. FEBS Lett 1995, 357:140-144.
86. Barrias CC, Lamghari M, Granja PL, Sa Miranda MC, Barbosa MA. Biological evaluation of calcium alginate microspheres as a vehicle for the localized delivery of a therapeutic enzyme. J BiomedMater Res A 2005, 74:545-552.
87. Discher DE, Eisenberg A. Polymer vesicles. Science 2002, 297:967-973.
88. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003, 2:347-360.
89. Torchilin VP. Multifunctional nanocarriers. Adv Drug Deliv Rev 2006, 58:1532-1555.
90. El-Sayed ME, Hoffman AS, Stayton PS. Smart polymeric carriers for enhanced intracellular delivery of therapeutic macromolecules. Expert Opin Biol Ther 2005, 5:23-32.
91. Kitchens KM, El-Sayed ME, Ghandehari H. Transepithelial and endothelial transport of poly (amidoamine) dendrimers. Adv Drug Deliv Rev 2005, 57:2163-2176.
92. Langer R. Drug delivery and targeting. Nature 1998, 392:5-10.
93. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001, 53:283-318.
94. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003, 55:329-347.
95. Ding BS, Dziubla T, Shuvaev VV, Muro S, Muzykantov VR. Advanced drug delivery systems that target the vascular endothelium. Mol Interv 2006, 6:98-112.
96. Hilgenbrink AR, Low PS. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J Pharm Sci 2005, 94:2135-2146.
97. Muro S, Koval M, Muzykantov V. Endothelial endocytic pathways: gates for vascular drug delivery. Curr Vasc Pharmacol 2004, 2:281-299.
98. Muzykantov V. Targeting drugs to pulmonary endothelium. Expert Opin Drug Deliv 2005, 2:909-926.
99. Muro S. VCAM-1 and ICAM-1. In: Aird WC, ed. Endothelial Biomedicine. New York: Cambridge University Press; 2007, 1058-1070.
100. Rothlein R, Dustin ML, Marlin SD, Springer TA. A human intercellular adhesion molecule (ICAM1) distinct from LFA-1. J Immunol 1986, 137:1270-1274.
101. Eniola AO, Krasik EF, Smith LA, Song G, Hammer DA. I-domain of lymphocyte function-associated antigen-1 mediates rolling of polystyrene particles on ICAM-1 under flow. Biophys J 2005, 89:3577-3588.
102. DeGraba T, Azhar S, Dignat-George F, Brown E, Boutiere B, et al. Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol 2000, 47:229-233.
103. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994, 76:301-314.
104. Hallahan DE, Virudachalam S. Intercellular adhesion molecule 1 knockout abrogates radiation induced pulmonary inflammation. Proc Natl Acad Sci USA 1997, 94:6432-6437.
105. Zhang W, Stanimirovic D. Current and future therapeutic strategies to target inflammation in stroke. Curr Drug Targets Inflamm Allergy 2002, 1:151-166.
106. Ni HT, Deeths MJ, Li W, Mueller DL, Mescher MF. Signaling pathways activated by leukocyte function-associated Ag-1-dependent costimulation. J Immunol 1999, 162:5183-5189.
107. Murciano JC, Muro S, Koniaris L, Christofidou-Solomidou M, Harshaw DW, et al. ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface. Blood 2003, 101:3977-3984.
108. Muro S, Schuchman EH, Muzykantov VR. Lysosomal enzyme delivery by icam-1-targeted nanocarriers bypassing glycosylation- and clathrin-dependent endocytosis. Mol Ther 2006, 13:135-141.
109. Muro S, Wiewrodt R, Thomas A, Koniaris L, Albelda SM, et al. A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1. J Cell Sci 2003, 116:1599-1609.
110. Muro S, Gajewski C, Koval M, Muzykantov VR. ICAM-1 recycling in endothelial cells: a novel pathway for sustained intracellular delivery and prolonged effects of drugs. Blood 2005, 105:650-658.
111. Muro S, Mateescu M, Gajewski C, Robinson M, Muzykantov VR, et al. Control of intracellular trafficking of ICAM-1-targeted nanocarriers by endothelial Na+/H+ exchanger proteins. Am J Physiol Lung Cell Mol Physiol 2006, 290:L809-L817.
112. Garnacho C, Shuvaev V, Thomas A, McKenna L, Sun J, et al. RhoA activation and actin reorganization involved in endothelial cam-mediated endocytosis of anti-PECAM carriers: critical role for tyrosine 686 in the cytoplasmic tail of PECAM-1. Blood 2008, 111:3024-3033.
113. Muro S, Garnacho C, Champion JA, Leferovich J, Gajewski C, et al. Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. Mol Ther 2008, 16:1450-1458.
114. Villanueva FS, Jankowski RJ, Klibanov S, Pina ML, Alber SM, et al. Microbubbles targeted to intercellular adhesion molecule-1 bind to activated coronary artery endothelial cells. Circulation 1998, 98: 1-5.
115. Weiner RE, Sasso DE, Gionfriddo MA, Thrall RS, Syrbu S, et al. Early detection of oleic acid-induced lung injury in rats using (111)In-labeled anti-rat intercellular adhesion molecule-1. J Nucl Med 2001, 42:1109-1115.
116. Finikova OS, Lebedev AY, Aprelev A, Troxler T, Gao F, et al. Oxygen microscopy by two-photon-excited phosphorescence. Chemphyschem 2008, 9: 1673-1679.
117. Muro S, Cui X, Gajewski C,Murciano JC, Muzykantov VR, et al. Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress. Am J Physiol Cell Physiol 2003, 285:C1339-C1347.
118. Garnacho C, Dhami R, Simone E, Dziubla T, Leferovich J, et al. Delivery of acid sphingomyelinase in normal and Niemann-Pick disease mice using intercellular adhesion molecule-1-targeted polymer nanocarriers. J Pharmacol Exp Ther 2008, 325:400-408.
119. Sakhalkar HS, Dalal MK, Salem AK, Ansari R, Fu J, et al. Leukocyte-inspired biodegradable particles that selectively and avidly adhere to inflamed endothelium in vitro and in vivo. Proc Natl Acad Sci U S A 2003, 100:15895-15900.
120. PavoineC, Pecker F. The sphingomyelinases: their regulation and roles in cardiovascular pathophysiology. Cardiovasc Res 2009, 82:175-183.